News & Trends - MedTech & Diagnostics
Molecular imaging to transform management of aggressive prostate cancer
MedTech News: A medical imaging technique known as PSMA PET/CT that provides detailed body scans while detecting levels of a molecule associated with prostate cancer could help doctors better tailor treatments for their patients, by determining the extent of disease spread at the time of diagnosis, a randomised controlled trial involving 300 patients in Australia published in The Lancet journal has found.
The approach combines two imaging technologies – positron emission tomography (PET) and computed tomography (CT) – and is almost one third more accurate than standard imaging at pinpointing the spread of prostate cancer throughout the body. PSMA PET/CT proved to be 92% accurate compared with only 65% accuracy with standard imaging.
Prostate cancer is commonly treated by surgery to remove the prostate or intensive radiotherapy to target the tumour. If there is a high risk the cancer may have spread to other parts of the body, patients may be offered medical imaging – typically CT and bone scans – to help doctors determine if additional treatments are needed.
Customer engagement during COVID-19. Health Industry Hub combines expertise in audience insights, delivering digital health content and measuring engagement with 20+ years industry experience. Created by industry for industry. Contact us.
Study lead Professor Michael Hofman of the Peter MacCallum Cancer Centre, Melbourne, said: “Taken together, our findings indicate that PSMA-PET/CT scans offer greater accuracy than conventional imaging and can better inform treatment decisions. We recommend that clinical guidelines should be updated to include PSMA PET/CT as part of the diagnostic pathway for men with high risk prostate cancer.”
Other findings of the study showed that PSMA-PET/CT had fewer uncertain findings than conventional imaging, resulted in half the radiation dose to patients and had a greater impact in changing patient management. 28% of men had the treatment plans changed the PSMA PET/CT scans compared to 15% following conventional imaging.
Professor Declan Murphy, senior author, of Peter MacCallum Cancer Centre, Melbourne, said, “Around one in three prostate cancer patients will experience a disease relapse after surgery or radiotherapy. This is partly because current medical imaging techniques often fail to detect when the cancer has spread, which means some men are not given the additional treatments they need. Our findings suggest PSMA-PET/CT could help identify these men sooner, so they get the most appropriate care.”
Associate Professor Roslyn Francis, co-author and scientific Chair of the Australasian Radiopharmaceutical Trials network, said: “Costs associated with PSMA-PET/CT vary in different regions of the world but this approach may offer savings over conventional imaging techniques. A full health-economic analysis will help to determine the cost effectiveness of introducing PSMA-PET/CT, both from a patient and a healthcare perspective”
Dr Stephen Mark, President of the Urological Society of Australia and New Zealand, welcomed the results saying “he results of this ground-breaking study have been eagerly anticipated and will be of great significance in the treatment of men with aggressive prostate cancer all around the world.”
The trial was conducted at 10 hospitals around Australia who were early adopters of this new technology. The ANZUP Cancer Trials Group supported the trial. ANZUP Chair, Professor Ian Davis, said, “This remarkable clinical trial brought together experts in nuclear medicine, surgery, oncology and clinical trials. This type of co-operative, academic trial is essential to producing the highest quality data leading to global changes in practice.”
Register FREE and join 20,000+ industry professionals who receive the latest industry news, innovations and insights from Health Industry Hub; the ONLY one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals.
The proPSMA study was funded by men’s health charity Movember via a partnership with the Prostate Cancer Foundation of Australia (PCFA). Dr Mark Buzza, Global Director of Prostate Cancer Biomedical Research at Movember said: “The research arising from the proPSMA study represents a really exciting development in novel imaging that will lead to the optimal management of men with high-risk prostate cancer. There is now solid evidence that PSMA PET/CT scans are the gold standard first-line imaging test for staging high-risk prostate cancer. We would like to see PSMA PET/CT scans adopted into clinical practice as soon as possible for this group of men.”
CEO of Prostate Cancer Foundation of Australia, Professor Jeff Dunn AO, hailed the study a game-changer. “These findings will transform the way we manage and treat prostate cancer, providing men around the world with much greater hope of combatting the disease effectively. Today we are one step closer to our vision of a future where no man dies of prostate cancer – standing on the shoulders of research leaders.”
News & Trends - Biotechnology
Depaz Oration to celebrate an ‘enduring’ legacy in the biotech sector
AusBiotech announced the establishment of the Depaz Oration, an annual keynote event that will debut at the AusBiotech Conference in […]
MoreNews & Trends - Pharmaceuticals
Government calls for public input on genomic-led cancer care
The Australian Government has launched a public consultation on a draft policy framework aimed at enhancing genomics-informed cancer care nationwide. […]
MoreNews & Trends - MedTech & Diagnostics
Can the patient voice reduce low-value care? Australia’s first large-scale hospital initiative seeks answers
In an Australian-first, a not-for-profit private health insurer will ask hospital patients to rate not only their clinical care but […]
MoreNews & Trends - Pharmaceuticals
Federal funding boosts national effort to tackle cardiovascular disease and stroke
The Australian Cardiovascular Alliance (ACvA) has secured vital Federal funding to accelerate its innovative national strategy aimed at combating cardiovascular […]
More